[1]王绥能,梁贤文,孙 光,等.伊立替康新辅助化疗在进展期胃癌的临床意义[J].医学信息,2018,31(24):164-166.[doi:10.3969/j.issn.1006-1959.2018.24.050]
　WANG Sui-neng,LIANG Xian-wen,SUN Guang,et al.Clinical Significance of Irinotecan Neoadjuvant Chemotherapy in Advanced Gastric Carcinoma[J].Journal of Medical Information,2018,31(24):164-166.[doi:10.3969/j.issn.1006-1959.2018.24.050]
点击复制

伊立替康新辅助化疗在进展期胃癌的临床意义()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年24期
页码:
164-166
栏目:
出版日期:
2018-12-15

文章信息/Info

Title:
Clinical Significance of Irinotecan Neoadjuvant Chemotherapy in Advanced Gastric Carcinoma
文章编号:
1006-1959（2018）24-0164-03
作者:
王绥能; 梁贤文; 孙 光; 侯开庆; 彭 勃
中南大学湘雅海口医院胃肠外科，海南 海口 570208
Author(s):
WANG Sui-neng; LIANG Xian-wen; SUN Guang; HOU Kai-qing; PENG Bo
Department of Gastroenterology,Xiangya Haikou Hospital,Central South University,Haikou570208,Hainan,China
关键词:
进展期胃癌; 新辅助化疗; 伊立替康; 亚叶酸钙; 5-氟尿嘧啶
Keywords:
Advanced gastric carcinoma; Neoadjuvant chemotherapy; Irinotecan; Leucovorin; 5-fluorouracil
分类号:
R735.2
DOI:
10.3969/j.issn.1006-1959.2018.24.050
文献标志码:
A
摘要:
目的 探索以伊立替康为主导的化疗方案对进展期胃癌新辅助化疗的可行性及安全性。方法 选择我院2008年6月~2017年10月收治的进展期胃癌患者73例，术前给予伊立替康、亚叶酸钙、5-氟尿嘧啶联合化疗两个周期后手术。记录患者化疗的有效率及毒副反应。结果 患者的毒副反应主要表现在血液系统及胃肠管系统，泌尿系统、心血管系统及神经系统未见明显不良反应。有1例因较为严重的骨髓抑制而提前结束化疗，其余均顺利完成。参照实体瘤疗效评估标准（RECIST），化疗有效率为78.13%，无效率为21.88%。结论 胃癌患者对伊立替康联合亚叶酸钙、5-氟尿嘧啶的新辅助化疗方案有较好的耐受性，且该方法有较好的疗效。
Abstract:
Objective To explore the feasibility and safety of irinotecan-based chemotherapy regimen for neoadjuvant chemotherapy for advanced gastric carcinoma.Methods 73 patients with advanced gastric carcinoma admitted to our hospital from June 2008 to October 2017 were enrolled. Two cycles after irinotecan, leucovorin and 5-fluorouracil were given before surgery. The chemotherapy efficiency and toxicity of the patients were observed. side effects.Results The patient's toxic and side effects were mainly manifested in the blood system and gastrointestinal system. No obvious adverse reactions were found in the urinary system, cardiovascular system and nervous system.1 patient had early termination of chemotherapy due to more severe myelosuppression, and the rest were successfully completed. According to the solid tumor evaluation criteria (RECIST), the effective rate of chemotherapy was 78.13%, and the ineffective rate was 21.88%.Conclusion Gastric carcinoma patients have better tolerance to irinotecan combined with calcium leucovorin and 5-fluorouracil, and this method has a good effect.

参考文献/References:

[1]Torre LA,Bray F,Siegel RL,et al.Global cancer statistics，2012[J].CA Cancer J Clin,2015,65(2):87-108.
[2]Patel SH,Kooby DA.Gastric adenocarcinoma surgery and adjuvant therapy[J].Surg Clin North Am,2011,91(5):1039-1077.
[3]刘怡,张珂诚.胃癌新辅助化疗疗效及影响因素分析[J].解放军医学院学报,2018,39(2):117-121.
[4]T heras se P,Arbuck SG,Eisenhauer EA,et al.New guide lines to evaluate the response to treatment in s olidtumors[J].J Natl Cancer In st,2000,92(3):205-216.
[5]杨喆,王国治.多西他赛联合顺铂、氟尿嘧啶和亚叶酸的新辅助化疗方案治疗不能切除进展期胃癌的疗效观察[J].中国癌症杂志,2016,16(5):346-350.
[6]Kim YW,Kim MJ,Ryu KW,et al.A phase Ⅱ study of periop-erative S1 combined with weekly decetaxel in patients with lo-cally advanced gastric carcinoma:clinical outcomes and clinico-pathological and pharmacogenetic predictors for survival[J].Gastric Cancer,2016,9(2):58-596.
[7]Kumagai K,Rouvelas I,Tsai JA,et al.Survival benefit and ad-ditional value of peoperative chemoradiotherapy in resectable gastric and gastro-oespahageal junction cancer:A direct and an-justed indirect comparison meta-analysis[J].Eur J Surg Oncol,2015,41(3):282-294.
[8]谢宝良,高凌.卡培他宾联合奥沙利铂术前新辅助化疗对进展期胃癌手术患者临床疗效的影响[J].现代肿瘤医学,2018,26(13):2076-2079.
[9]郭佳栋,张雪梅.8种治疗胃癌常用抗肿瘤药物致不良反应病例报告分析[J].中国药房,2016,27(33):4627-4630.

相似文献/References:

[1]屈欣然.DCE-MRI对局部进展期乳腺癌新辅助化疗的临床指导价值研究[J].医学信息,2018,31(04):34.[doi:10.3969/j.issn.1006-1959.2018.04.012]
　QU Xin-ran.Clinical Value of DCE-MRI in Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer[J].Journal of Medical Information,2018,31(24):34.[doi:10.3969/j.issn.1006-1959.2018.04.012]
[2]王文重,伊 扬,董晓昕,等.食管癌患者新辅助化疗前后生理指标变化及意义[J].医学信息,2022,35(09):116.[doi:10.3969/j.issn.1006-1959.2022.09.029]
　WANG Wen-zhong,YI Yang,DONG Xiao-xin,et al.Changes and Significance of Physiological Indexes in Esophageal Cancer Patients Before and After Neoadjuvant Chemotherapy[J].Journal of Medical Information,2022,35(24):116.[doi:10.3969/j.issn.1006-1959.2022.09.029]
[3]张 虎,张 涛,徐 芳,等.MRI在乳腺癌诊治中的研究进展[J].医学信息,2022,35(10):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
　ZHANG Hu,ZHANG Tao,XU Fang,et al.Research Progress of MRI in Diagnosis and Treatment of Breast Cancer[J].Journal of Medical Information,2022,35(24):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
[4]肖宝强,张 霆,孙新增,等.腹腔镜与开腹根治术对进展期胃癌患者的近期疗效、 应激水平、免疫功能影响的差异性研究[J].医学信息,2018,31(14):75.[doi:10.3969/j.issn.1006-1959.2018.14.022]
　XIAO Bao-qiang,ZHANG Ting,SUN Xin-zeng,et al.Differences between Laparoscopic and Open Radical Resection for Short-term Efficacy, Stress Level and Immune Function in Patients with Advanced Gastric Cancer[J].Journal of Medical Information,2018,31(24):75.[doi:10.3969/j.issn.1006-1959.2018.14.022]
[5]苏 志,吴 蔚,吴智钢,等.含洛铂方案新辅助化疗结合保肢手术治疗骨肉瘤的临床疗效观察[J].医学信息,2018,31(21):83.[doi:10.3969/j.issn.1006-1959.2018.21.022]
　SU Zhi,WU Wei,WU Zhi-gang,et al.Clinical Efficacy of Neoadjuvant Chemotherapy with Lobaplatin Combined with Limb Salvage Surgery for OsteosarcomaC[J].Journal of Medical Information,2018,31(24):83.[doi:10.3969/j.issn.1006-1959.2018.21.022]
[6]黄 雨,楼浩男,涂 刚.Luminal B型乳腺癌TEC新辅助化疗疗效及影响因素分析[J].医学信息,2019,32(04):104.[doi:10.3969/j.issn.1006-1959.2019.04.033]
　HUANG Yu,LOU Hao-nan,TU Gang.Analysis of the Efficacy and Influencing Factors of Neoadjuvant Chemotherapy for Luminal B Breast Cancer[J].Journal of Medical Information,2019,32(24):104.[doi:10.3969/j.issn.1006-1959.2019.04.033]
[7]李 博,李春晓.新辅助化疗在宫颈癌治疗中的应用[J].医学信息,2019,32(15):106.[doi:10.3969/j.issn.1006-1959.2019.15.034]
　LI Bo,LI Chun-xiao.Application of Neoadjuvant Chemotherapy in the Treatment of Cervical Cancer[J].Journal of Medical Information,2019,32(24):106.[doi:10.3969/j.issn.1006-1959.2019.15.034]
[8]关利平,李建文.凝血相关指标与乳腺癌新辅助化疗疗效预测的相关性研究[J].医学信息,2022,35(16):159.[doi:10.3969/j.issn.1006-1959.2022.16.041]
　GUAN Li-ping,LI Jian-wen.Study on Correlation Between Coagulation- related Indexes and Efficacy Prediction of Neoadjuvant Chemotherapy for Breast Cancer[J].Journal of Medical Information,2022,35(24):159.[doi:10.3969/j.issn.1006-1959.2022.16.041]
[9]付大鹏.多西他赛联合表柔比星新辅助化疗治疗乳腺癌的效果[J].医学信息,2020,33(05):149.[doi:10.3969/j.issn.1006-1959.2020.04.048]
　FU Da-peng.Evaluation of Docetaxel Combined with Epirubicin Neoadjuvant Chemotherapy for Breast Cancer[J].Journal of Medical Information,2020,33(24):149.[doi:10.3969/j.issn.1006-1959.2020.04.048]
[10]王羽翎,孙佳威,周显礼.二维及三维实时剪切波弹性成像在乳腺肿块评估中的应用[J].医学信息,2020,33(11):42.[doi:10.3969/j.issn.1006-1959.2020.11.014]
　WANG Yu-ling,SUN Jia-wei,ZHOU Xian-li.Application of 2D and 3D Real-time Shear Wave Elastography in Breast Mass Evaluation[J].Journal of Medical Information,2020,33(24):42.[doi:10.3969/j.issn.1006-1959.2020.11.014]

更新日期/Last Update: 2019-01-09